| Target Molecule | Cyclic Somatostatin (Somatostatin-14) |
| Synonyms | SRIF-14; SST-14; growth hormone release-inhibiting factor (GHIH); somatotropin release-inhibiting factor |
| CAS Number | 38916-34-6 (also reported as 51110-01-1) |
| Sequence (3-Letter) | H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH |
| Sequence (1-Letter) | AGCKNFFWKTFTSC (14 residues; free-acid C-terminus) |
| Disulfide Bridge | Cys3–Cys14 (intramolecular ring) |
| Molecular Formula | C₇₆H₁₀₄N₁₈O₁₉S₂ |
| Molecular Weight | 1637.9 |
| Service Category | Custom Synthesis / Pharmaceutical Peptide R&D |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98%, ≥99% by HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate or TFA (per specification) |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) with Controlled Oxidation |
| Modification Options | Isotopic labeling, sequence truncations, specific counter-ions |
| Available Scale | Milligram (R&D) to Kilogram (Commercial Manufacturing) |
| Analytical Data | Comprehensive COA, HPLC, MS provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, pharmaceutical R&D, and industrial manufacturing. Not a finished drug. |
Cyclic Somatostatin (CAS 38916-34-6) is a fourteen-amino-acid synthetic peptide constrained by an intramolecular disulfide bridge between Cys3 and Cys14. We synthesize this specific structure as a high-purity raw material for receptor binding studies and pharmaceutical development.
We utilize optimized solid-phase peptide synthesis (SPPS) followed by controlled oxidation to form the essential Cys3–Cys14 disulfide bond. This platform ensures highly efficient amino acid coupling and precise conformational locking, yielding batches that meet rigorous HPLC purity specifications.
Yes. The standard structure requires a specific disulfide ring to maintain the active conformation of the central Phe-Trp-Lys-Thr motif. Our modification services can add targeted isotopic labels, specific counter-ions (such as TFA to acetate conversions), or sequence truncations to suit specific physical chemistry requirements for advanced R&D.
Our infrastructure transitions seamlessly from milligram-scale laboratory batches to kilogram-scale commercial production. We maintain rigorous batch-to-batch consistency essential for industrial-scale pharmaceutical formulation.
We serve as a strategic technical partner. Our team assists with sequence stability testing, impurity profiling, and the provision of complete analytical documentation to accelerate downstream project timelines.
Cyclic Somatostatin, defined by the sequence AGCKNFFWKTFTSC and referenced as Somatostatin-14, is a widely utilized scaffold for building receptor-targeted therapeutics and delivery systems. Synpeptide provides comprehensive synthetic solutions for this target molecule, leveraging our technical expertise to support industrial pharmaceutical R&D.
Through our established peptide synthesis platform, we achieve efficient coupling of the 14-residue sequence via optimized Solid-Phase Peptide Synthesis (SPPS). We execute precise, controlled oxidation to form the essential Cys3–Cys14 disulfide bridge, strictly controlling impurity profiles during manufacturing to ensure the final material meets exact purity specifications (routinely ≥98% via HPLC). This rigorous process control guarantees the reproducibility required for advanced research and commercial applications.
A key feature of Somatostatin-14 is the disulfide ring, which ties positions three and fourteen together to lock the central residues into the necessary conformation for receptor binding. Beyond this baseline, we offer extensive peptide modification services. Researchers can request targeted isotopic labeling for tracking studies, specific counter-ion exchanges to adjust solubility profiles, or the development of smaller cyclic analogues that retain somatostatin-like activity.
Scaling a disulfide-bridged peptide from benchtop research to commercial application demands stable manufacturing protocols. We facilitate efficient large-scale peptide synthesis for Cyclic Somatostatin, managing the transition from milligram screening batches to kilogram-scale production. Our large-scale infrastructure ensures a continuous, reliable supply chain for pharmaceutical developers, supported by complete analytical documentation including COA, MS, and HPLC data.
Beyond raw material manufacturing, we act as a technical partner for one-stop cyclic peptide R&D. We actively assist clients in sequence stability assessments, impurity profiling, and degradation analysis. Whether integrating Cyclic Somatostatin into receptor signaling research or utilizing it as a reference comparator in analogue development, our engineering team provides the precise analytical data and synthetic capacity required to execute complex R&D projects efficiently.
